医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Harlan Laboratories Announces Invenium Pharmacology as Agent for Southeast Asia, Australia and New Zealand

2014年04月23日 PM05:00
このエントリーをはてなブックマークに追加


 

ITINGEN, Switzerland

Harlan Laboratories, Ltd., a privately held provider of general and specialty toxicology services, announces the appointment of Invenium Pharmacology as its exclusive agent for Harlan’s Contract Research Services (CRS) in Australia, Southeast Asia and New Zealand.

Through the agency agreement, Harlan CRS will strengthen its local presence in the pharmaceutical and chemical industries across the region. Anthony Bishop of Invenium Pharmacology will take on the primary contact role in the region.

With more than 15 years of experience in pharmaceutical companies and contract research organizations, Bishop brings extensive experience in business development, global project management and sales to Harlan CRS.

As the local agent for Harlan CRS, Bishop will provide leadership and management expertise to connect drug development companies with the services and insight they need to advance their programs. This agreement also positions Harlan CRS for continued growth on a global scale.

“There are great growth opportunities for Harlan CRS in this region,” said Ciriaco Maraschiello, director of strategic initiatives and director of drug discovery and translational medicine at Harlan CRS. “Working with Anthony Bishop and Invenium Pharmacology, we can provide the expertise that companies and organizations in this region need — at a local level.”

About Harlan Laboratories, Ltd.

Harlan Laboratories, Ltd., a subsidiary of Harlan Laboratories, Inc., provides general and specialty toxicology services through its Contract Research Services business to the global chemical, agrochemical and pharmaceutical industries. With laboratory locations in Germany, Spain, Switzerland and the UK, Harlan and its affiliates are focused on providing customers with services to optimize product development. Please visit www.Harlan.com/CRS.

CONTACT

For Harlan Laboratories, Ltd.
Lea Studer, +1 308-237-5567
lea@scorrmarketing.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作